Cayenne Wellness Center announces 5th annual Hispanic Heritage Month Educational Summit in Long Beach. Aug 17, 2026 The event brings Hispanic Heritage Month and National Sickle Cell Awareness Month together to advance education, health equity, advocacy, and access to care GLENDALE, CA, August 17, 2026 /24-7PressRelease/ - Join New Jersey News Today in commemorating two significant months with a blend of impactful programming, deep community connections, and shared momentum for change. New Jersey News Today is thrilled to acknowledge the vital role of its sponsors in bringing these celebrations to life, starting with its headline supporters. Cayenne Wellness Center proudly recognizes the invaluable contribution of its key sponsors as New Jersey News Today gear up for upcoming events honoring National Sickle Cell Awareness Month and Hispanic Heritage Month. Beam Therapeutics, Inc. stands tall as a GOLD sponsor, while Chiesi USA, Inc. and Global Rare Diseases graciously serve as its SILVER sponsors for the Hispanic Heritage Summit on September 15 to 16, 2026, at the Marriott Long Beach Downtown in Long Beach, California. Event Details: Dates: September 15-16, 2026 Location: Long Beach, CA & Online Target Audience: Designed for healthcare professionals, educators, social workers, students, Hispanic and Latino individuals and families affected by sickle cell disease, and members of the broader community. The two-day educational summit aims to unite sickle cell warriors, caregivers, healthcare professionals, advocates, community leaders, organizations, and families to shed light on sickle cell disease. It will also specifically address the unique experiences and challenges faced by Hispanic and Latino individuals and families affected by the condition. The summit will feature culturally relevant education, community voices, advocacy, and dialogue focused on improving awareness, health equity, and access to quality sickle cell care. The timing of this year's summit carries special significance. September is National Sickle Cell Awareness Month, a time dedicated to increasing understanding of sickle cell disease and elevating the voices and experiences of those living with the condition. The summit also begins on September 15, the opening of Hispanic Heritage Month, creating a timely opportunity to bring greater visibility to the intersection of culture, health, identity, and sickle cell disease. Programming will explore the relationship between country of origin, genetic background, and community-centered sickle cell education, while providing practical tools to help warriors advocate for themselves and navigate sickle cell disease, comorbidities, and related health concerns. A central part of the summit will be the inclusion of lived experience. A warrior-led roundtable will create space for individuals living with sickle cell disease to share their perspectives and experiences directly with attendees. The program will also address the important transition from pediatric to adult care, and feature breakout discussions focused on men's health and sickle cell disease, women's health and sickle cell disease, international sickle cell warriors, and domestic and international providers and caregivers. Beyond the educational sessions, the summit is designed to strengthen relationships across the sickle cell community. Vendor and exhibitor tables are available for community-based organizations, businesses, healthcare organizations, authors, artists, educational institutions, industry partners, and others interested in sharing resources and connecting directly with summit participants. Through education, storytelling, advocacy, resource-sharing, and community connection, Cayenne Wellness Center's Hispanic Heritage Month Educational Summit aims to expand awareness of sickle cell disease within Hispanic and Latino communities and strengthen pathways to culturally responsive information, resources, support, and care. Registration Is Now Open Sickle cell warriors, families, caregivers, healthcare professionals, advocates, community organizations, and other interested attendees are invited to participate. Register to attend: https://cayennewellness.org/espanol/hispanic-heritage-virtual-seminar-2026 Vendor & Exhibitor Opportunities Organizations and businesses interested in connecting with attendees are invited to reserve a vendor or exhibitor table. Opportunities are available for community organizations, healthcare organizations, authors, artists, businesses, educational institutions, and industry partners. Reserve a vendor or exhibitor table: https://tinyurl.com/HHVENDOR2026 Cayenne Wellness Center and Children's Foundation is a 501(c)(3) nonprofit organization established in 2000 and dedicated to improving the quality of life for individuals living with sickle cell disease in California. The organization provides expert, unbiased, and comprehensive care while promoting education, advocacy, and awareness for healthcare providers, patients, and the wider community. With a strong grassroots network and a commitment to equity, Cayenne Wellness continues to be a trusted leader in advancing sickle cell support and resources. Learn more and get involved at CayenneWellness.org. Follow Cayenne Wellness Center on: Facebook: facebook.com/CayenneWellness Instagram: instagram.com/CayenneWellness X (formerly Twitter): @CayenneWellness YouTube: youtube.com/@CayenneWellness Read the original story here: https://www.24-7pressrelease.com/press-release/537770/cayenne-wellness-center-announces-5th-annual-hispanic-heritage-month-educational-summit-in-long-beach Press Release Service and Press Release Distribution by 24-7 Press Release Newswire Looking for Local Media Coverage in the United States of America? New Jersey News Today has a place for all 50 States at the State News Network

Beam Therapeutics (NASDAQ:BEAM) downgraded by Wall Street Zen to "Strong Sell" August 16, 2026 Key points. * Wall Street Zen downgraded Beam Therapeutics to "Strong Sell" from "Sell," although the broader analyst consensus remains "Moderate Buy" with an average price target of $49. * Beam reported weaker-than-expected quarterly results, including an adjusted loss of $1.18 per share versus estimates of $1.11 and revenue of $0.49 million versus expectations of $16.37 million; revenue fell 94.2% year over year. * The stock opened at $26.75, below its 50-day average of $30.26, while insiders sold roughly $10.5 million worth of shares over the past 90 days. * MarketBeat previews top five stocks to own in September. Beam Therapeutics (NASDAQ:BEAM - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "sell" rating to a "strong sell" rating in a research report issued to clients and investors on Sunday. BEAM has been the subject of a number of other research reports. Sanford C. Bernstein lowered their price target on Beam Therapeutics from $40.00 to $39.00 and set an "outperform" rating for the company in a research report on Wednesday, May 13th. HC Wainwright reissued a "buy" rating on shares of Beam Therapeutics in a report on Monday, August 10th. Bank of America restated a "buy" rating and issued a $47.00 price objective on shares of Beam Therapeutics in a research note on Wednesday, July 8th. Tudor Pickering set a $39.00 target price on Beam Therapeutics in a report on Wednesday, May 13th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Beam Therapeutics in a research report on Friday, July 17th. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $49.00. Beam Therapeutics trading up 0.9%. NASDAQ BEAM opened at $26.75 on Friday. Beam Therapeutics has a 12-month low of $15.60 and a 12-month high of $38.26. The company has a fifty day simple moving average of $30.26 and a two-hundred day simple moving average of $28.80. The company has a current ratio of 14.57, a quick ratio of 14.57 and a debt-to-equity ratio of 0.09. The stock has a market cap of $2.76 billion, a P/E ratio of -31.10 and a beta of 2.23. Discover more Stocks & Bonds Stock average calculator Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($1.18) earnings per share for the quarter, missing analysts' consensus estimates of ($1.11) by ($0.07). Beam Therapeutics had a negative net margin of 54.75% and a negative return on equity of 30.71%. The company had revenue of $0.49 million for the quarter, compared to analysts' expectations of $16.37 million. During the same period last year, the firm earned ($1.00) earnings per share. Beam Therapeutics's quarterly revenue was down 94.2% compared to the same quarter last year. On average, analysts forecast that Beam Therapeutics will post -4.49 earnings per share for the current year. Insider buying and selling at Beam Therapeutics. In other news, insider Fmr Llc sold 251,488 shares of the company's stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $35.26, for a total value of $8,867,466.88. Following the sale, the insider owned 854,583 shares in the company, valued at $30,132,596.58. This represents a 22.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Amy Simon sold 16,667 shares of the firm's stock in a transaction dated Monday, July 27th. The stock was sold at an average price of $25.74, for a total value of $429,008.58. Following the sale, the insider directly owned 85,696 shares in the company, valued at approximately $2,205,815.04. This trade represents a 16.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 301,527 shares of company stock worth $10,468,500. 3.80% of the stock is owned by corporate insiders. Hedge funds weigh in on Beam Therapeutics. Several institutional investors have recently made changes to their positions in BEAM. Jones Financial Companies Lllp boosted its holdings in Beam Therapeutics by 55,780.0% during the first quarter. Jones Financial Companies Lllp now owns 33,528 shares of the company's stock worth $655,000 after buying an additional 33,468 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Beam Therapeutics by 10.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 438,529 shares of the company's stock worth $8,564,000 after acquiring an additional 42,609 shares during the period. Prudential Financial Inc. purchased a new stake in shares of Beam Therapeutics during the 2nd quarter worth about $201,000. New York State Common Retirement Fund boosted its stake in shares of Beam Therapeutics by 17.7% during the 2nd quarter. New York State Common Retirement Fund now owns 30,629 shares of the company's stock worth $521,000 after acquiring an additional 4,600 shares in the last quarter. Finally, Invesco Ltd. boosted its stake in shares of Beam Therapeutics by 46.0% during the 2nd quarter. Invesco Ltd. now owns 128,874 shares of the company's stock worth $2,192,000 after acquiring an additional 40,583 shares in the last quarter. 99.68% of the stock is owned by hedge funds and other institutional investors. About Beam Therapeutics. Beam Therapeutics, Inc NASDAQ: BEAM is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need. Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Beam Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beam Therapeutics wasn't on the list. While Beam Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.